期刊文献+

多发性骨髓瘤临床特征与预后分析 被引量:2

Analysis of multiple myeloma clinical feature and prognosis
下载PDF
导出
摘要 目的探讨多发性骨髓瘤(MM)临床特征与预后的关系。方法回顾性分析2010年1月~2015年5月本院初诊的53例MM患者的临床特点与实验室指标。采用SPSS 17.0软件进行数据统计及分析,通过单因素及多因素分析,探讨其预后影响因素。结果单因素分析显示,年龄、血红蛋白、血清钙、白蛋白、β_2微球蛋白(β_2-MG)、乳酸脱氢酶(LDH)、血肌酐水平为MM预后的相关因素。COX多因素分析显示,年龄、血清β_2-MG是MM的独立预后因素。ISS分期中,Ⅰ、Ⅱ、Ⅲ期患者的中位生存期比较,差异有统计学意义(P=0.000)。DS分期中,Ⅰ、Ⅱ、Ⅲ期患者的中位生存期比较,差异无统计学意义(P=0.917)。结论高龄、高血清β_2-MG MM患者的预后较差,ISS分期更适用于预后评估。 Objective To explore the relationship between clinical feature and prognosis of multiple myeloma(MM).Methods The clinical characteristics and laboratory index of 53 patients with diagnosis of MM in our hospital from January 2010 to May 2015 were reviewed.SPSS 17.0 software was used for data statistics and analysis.Through univariate and multivariate analysis,the prognostic factors were explored. Results Univariate analysis showed that age,hemoglobin,serum calcium,albumin,β_2-microglobulin(β_2-MG),lactate dehydrogenase(LDH) and serum creatinine were related factors in MM prognosis.Multivariate analysis showed that age and β_2-MG were independent prognostic factors for MM.There was significant difference in median survival time among the grade Ⅰ,Ⅱ,Ⅲ according to ISS staging(P=0.000).There was no significant difference in median survival time among the grade Ⅰ,Ⅱ,Ⅲ according to DS staging(P=0.917). Conclusion High level of β_2-MG and old age are correlated to poor prognosis.ISS staging would be more suitable for the evaluation of prognosis.
作者 沈君 王开泰
出处 《中国当代医药》 2016年第11期39-41,共3页 China Modern Medicine
基金 上海市宝山区卫生青年医学人才培养计划资助项目(bswsyq-2015-A07)
关键词 多发性骨髓瘤 临床特征 预后因素 Multiple myeloma Clinical feature Prognostic factor
  • 相关文献

参考文献20

二级参考文献69

  • 1高津,傅晋翔,张宏.T-VAD和VAD方案治疗多发性骨髓瘤的疗效观察[J].中国血液流变学杂志,2008,18(1):75-77. 被引量:6
  • 2袁宇宁,张星星,朱绮文.沙利度胺联合VAD方案治疗多发性骨髓瘤的临床研究[J].临床血液学杂志,2004,17(4):209-211. 被引量:42
  • 3黄丽芳,孔卫红,雷凯雄.沙利度胺与地塞米松联合治疗多发性骨髓瘤的临床研究[J].南华大学学报(医学版),2007,35(2):207-209. 被引量:1
  • 4Hicks LK,Haynes AE,Reece DE,et aI. A meta-analysis and systemat- ic review of thalidomide for patients with previously untreated multiple myeloma [J]. Cancer Treat Rev, 2008,5 (34) : 442-452. 被引量:1
  • 5Kagoya Y ,Nannya Y ,Kurokawa M. Thalidomide maintenance therapy for patients with multiple myeloma:meta-analysis [J] Leuk Res, 2012,36(8) :1016-1021. 被引量:1
  • 6Brenner H, Gondos A, Pulte D. term survival of younger patients Recent major improvement in long- with multiple myeloma [J]. Blood, 2008, 111: 2521-2526. 被引量:1
  • 7Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55: 74-108. 被引量:1
  • 8Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CACancer J Clin, 2012, 62: 10-29. 被引量:1
  • 9Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON- 65/GMMG-HD4 randomized phase HI trial comparing bortezomib, doxorubicin, dexamethasone (PAD) Vs VAD followed by high-dose melphalan (HI)M) and maintenance with bortezomib or thalidomide iIn patients with newly diagnosed multiple myeloma (MM)[J]. ASH Annual Meeting Abstracts, 2010, 116: 40. 被引量:1
  • 10Rosino| L, Cibeira MT, Mateos MV, et al. Phase 1~ PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib[J]. ASH Annual Meeting Abstracts, 2010, 116: 307. 被引量:1

共引文献92

同被引文献15

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部